Physician profile
Patrick B Gregory
NPI 1447245964
$1,564.90
in general payments reported to CMS, 2019-2025
17 companies · $273 in 2025
The $273 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $34.90 · 2021: $54.19 · 2022: $154 · 2023: $631 · 2024: $206 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,109.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $418.84 | 2023-2025 | Cardiomems |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $223.07 | 2019-2025 | Lifevest |
| Medtronic, INC. | $165.35 | 2022-2023 | Reveal Linq |
| Novartis Pharmaceuticals Corporation | $144.27 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $132.18 | 2019-2023 | Xarelto |
| Amgen INC. | $106.16 | 2024-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $91.87 | 2019-2024 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.29 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $52.37 | 2024-2025 | Brilinta |
| Abiomed | $35.73 | 2024 | Impella |
| Boston Scientific Corporation | $25.92 | 2021 | |
| Novo Nordisk INC | $23.69 | 2024 | Ozempic |
| Kiniksa Pharmaceuticals International, Plc | $16.42 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $15.47 | 2024 | |
| Pfizer INC. | $14.35 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $13.95 | 2022 | |
| Amarin Pharma, INC. | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Gregory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.